Abstract
We tested the effect of bestatin [(2S, 3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-leucine] on the serum levels of various hydrolytic enzymes in a patient with progressive muscular dystrophy. Long-term administration of bestatin significantly suppressed the serum levels of aspartate aminopeptidase, arginine aminopeptidase, carboxypeptidase, alkaline phosphatase, and esterase. The results of multivariate study performed on the enzyme networks are compatible with the notion that this drug has a synchronizing effect on the movements of enzyme networks. Although in this middle-aged patient with an established disease the levels of enzymes of muscular origin were not significantly suppressed by this treatment, the present findings may warrant a therapeutic trial with this agent on young patients with initial symptoms of the disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
